June 2013 Editor's Picks: Products from Brabender Pharma and K-Tron - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

June 2013 Editor's Picks: Products from Brabender Pharma and K-Tron

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Brabender Pharma
Tabletop twin-screw extruder features easy cleaning.

Brabender Pharma’s PTSE 12/36 EC tabletop, 12-mm pharmaceutical twin-screw extruder is suitable for hot-melt extrusion (HME), early formulation development, and preparation of samples for clinical studies. The more compact addition to the company’s product line enhances the ability to address the challenges of HME in feasibility studies. The extruder has a removable barrel liner and a horizontally split barrel to allow quick access and ease of cleaning and sterilization. Two additional openings can be used as downstream feeding or venting ports. Segmented screws can be configured to customer specifications and optional ports can be added on request.


K-Tron
Micro-ingredient feeder has high accuracy for low feedrates.

K-Tron’s low-rate, micro-ingredient feeder line now includes the MT16 with a 16-mm feed screw and a overall feedrate capacity of 0.02 dm³/hr to 27 dm³/hr. The feeder is ideal for applications feeding high-value additives or APIs in pharmaceutical processes that require a high degree of accuracy. The unit can be used with the MT12-mm and MT16-mm twin-screw or single-screw feeder modules. The interchangeable screws provide versatility to handle a broad range of materials. The unit has a smaller overall profile and footprint that allows for closer discharge dimensions and is ideal for multi-ingredient cluster arrangements. The design also allows for extended screw profiles. The unit is easy to take apart, clean, and maintain with a totally enclosed weight sensor.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here